1. |
Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis[J]. Am J Med, 1988, 85(6): 771-774.
|
2. |
Diouf ML, Diallo S, Mbengue M, et al. Methotrexate, liver and rheumatoid arthritis in tropical areas[J]. Sante, 2001, 11(3): 195-200.
|
3. |
Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow up study[J]. Arthritis Rheum, 2003, 48(6): 1513-1520.
|
4. |
The European Agency for the Evaluation of Medicinal Products. EMEA issues public statement on leflunomide[J]. Reactions Weekly, 2001, 844(6): 2.
|
5. |
Health Canada. Leflunomide (Arava): hematologic, hepatic and respiratory reactions[J]. Can Newsletter, 2002, 12(1): 2-3.
|
6. |
Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide[J]. Ann Rheum Dis, 2010, 69(1): 43-47.
|
7. |
Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis[J]. Arthritis Rheum,1999, 42(6): 1322-1328.
|
8. |
Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative[J]. Ann Rheum Dis, 2009, 68(7): 1086-1093.
|
9. |
Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?[J].J Rheumatol, 2002, 29(8): 1586-1589.
|
10. |
梁柳琴, 杨岫岩. 甲氨蝶呤:安全、有效、价廉的抗风湿药[J]. 新医学, 2001, 32(5): 309-311.
|
11. |
Arena U, Stasi C, Mannoni A, et al. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis[J]. Dig Liver Dis, 2012, 44(2): 149-153.
|
12. |
Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy, Conflict between guidelines for rheumatologists and dermatologists[J]. Ann Rheum Dis, 1996, 55(5): 273-275.
|
13. |
Merino-Sanjuán M, Carrera A, Monte E, et al. Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro[J]. Int J Pharm, 2004, 278(2): 283-291.
|
14. |
Fernández Megía MJ, Alós Almiñana M, Terol Castera MJ. Managing methotrexate toxicity: a case report[J]. Farm Hosp, 2004, 28(5): 371-374.
|
15. |
Sotoudehmanesh R, Anvari B, Akhlaghi K, et al. Methotrexate hepatotoxicity in patients with rheumatoid arthritis[J]. Middle East Journal of Digestive Diseases, 2010, 2(2): 104-109.
|
16. |
Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group [J]. N Engl J Med, 1995, 333(3): 137-141.
|
17. |
Ferraccioli GF, Gremese E, Tomoetto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years[J]. Rheumatology (Oxford), 2002, 41(8): 892-898.
|
18. |
Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion[J]. Joint Bone Spine, 2006, 73(4): 388-395.
|
19. |
Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2009, 68(7): 1105-1112.
|
20. |
Grove ML, Hassell AB, Hay EM, et al. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice[J]. QJM, 2001, 94(6): 309-319.
|
21. |
Hoekstra M, Haagsma CJ, Doelman CJ, van de Laar MA, et al. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate[J]. Ann Rheum Dis, 2005, 64(1):141-143.
|